Want to see AGIO full AI Analyst Report?
Total Valuation
Agios Pharma has a market cap or net worth of $1.79B. The enterprise value is $1.62K.
Market Cap$1.79B
Enterprise Value$1.62K
Share Statistics
Agios Pharma has 59,701,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,701,880
Owned by Insiders1.16%
Owned by Institutions4.18%
Financial Efficiency
Agios Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.18%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-38.18%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee100.05K
Profits Per Employee-764.41K
Employee Count540
Asset Turnover0.04
Inventory Turnover0.35
Valuation Ratios
The current PE Ratio of Agios Pharma is ―. Agios Pharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio29.21
PB Ratio1.32
Price to Fair Value1.32
Price to FCF-4.18
Price to Operating Cash Flow-4.84
PEG Ratio0.02
Income Statement
In the last 12 months, Agios Pharma had revenue of 54.03M and earned -412.78M in profits. Earnings per share was -7.12.
Revenue54.03M
Gross Profit42.51M
Operating Income-472.13M
Pretax Income-413.80M
Net Income-412.78M
EBITDA-408.62M
Earnings Per Share (EPS)-7.12
Cash Flow
In the last 12 months, operating cash flow was -360.60M and capital expenditures -4.66M, giving a free cash flow of -365.25M billion.
Operating Cash Flow-360.60M
Free Cash Flow-365.25M
Free Cash Flow per Share-6.12
Dividends & Yields
Agios Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.86
52-Week Price Change-16.98%
50-Day Moving Average34.19
200-Day Moving Average31.63
Relative Strength Index (RSI)47.24
Average Volume (3m)1.16M
Important Dates
Agios Pharma upcoming earnings date is Oct 29, 2026, TBA (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Agios Pharma as a current ratio of 11.46, with Debt / Equity ratio of 3.04%
Current Ratio11.46
Quick Ratio11.06
Debt to Market Cap0.03
Net Debt to EBITDA0.07
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Agios Pharma has paid -1.02M in taxes.
Income Tax-1.02M
Effective Tax Rate<0.01
Enterprise Valuation
Agios Pharma EV to EBITDA ratio is -3.80, with an EV/FCF ratio of -4.11.
EV to Sales28.71
EV to EBITDA-3.80
EV to Free Cash Flow-4.11
EV to Operating Cash Flow-4.16
Balance Sheet
Agios Pharma has $617.58M in cash and marketable securities with $31.17M in debt, giving a net cash position of $586.40M billion.
Cash & Marketable Securities$617.58M
Total Debt$31.17M
Net Cash$586.40M
Net Cash Per Share$9.82
Tangible Book Value Per Share$20.58
Margins
Gross margin is 87.92%, with operating margin of -873.87%, and net profit margin of -764.01%.
Gross Margin87.92%
Operating Margin-873.87%
Pretax Margin-765.89%
Net Profit Margin-764.01%
EBITDA Margin-756.31%
EBIT Margin-765.89%
Analyst Forecast
The average price target for Agios Pharma is $41.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$41.00
Price Target Upside12.76% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast140.58%
EPS Growth Forecast-161.11%